Baxter International will acquire Synovis Life Technologies, a provider of biological and mechanical products for soft tissue repair used in a variety of surgical procedures for. The $260 million acquisition ($325 million in equity value) is intended to expand the portfolio of Baxter’s regenerative medicine and biosurgery franchise, which includes a number of devices and biological products for hemostasis, tissue sealing and adherence. The Synovis board has unanimously approved the transaction. ...